The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 75 mg, 110 mg, and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran Etexilate capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients; treatment and reduction of the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/vA6N7Hx
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment